Effectiveness of the Japanese DOLOPLUS-2: a pain assessment scale for patients with moderate-to-severe dementia

被引:6
|
作者
Ando, Chiaki [1 ]
Ito, Yoshinori [2 ]
Amemiya, Shimon [2 ]
Tamura, Kyoko [2 ]
Kako, Ken [2 ]
Tsuzura, Satoko [2 ]
Yoshida, Ryoichi [2 ]
Hishinuma, Michiko [3 ]
机构
[1] Bunkyo Gakuin Univ, Dept Nursing Sci, Fac Hlth Sci Technol, Tokyo, Japan
[2] Yokufukai Geriatr Hosp, Dept Neurol, Tokyo, Japan
[3] St Lukes Int Univ, Dept Nursing Sci, Tokyo, Japan
关键词
moderate-to-severe dementia; observational instrument; pain assessment; ALZHEIMERS-DISEASE; OLDER-ADULTS; MANAGEMENT; STATE;
D O I
10.1111/psyg.12168
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
BackgroundThis study aimed to assess whether the Japanese DOLOPLUS-2 scale could effectively identify pain in elderly individuals with moderate-to-severe dementia. MethodsThis study used a pre-test/post-test design with purposive sampling to select an experimental group and a historical control group. The inclusion criteria were a Functional Assessment Staging score of 5 or 6, a diagnosis of an orthopaedic disease that typically involves pain, the ability to say I am currently in pain' (to prevent medication errors), and a total DOLOPLUS-2 scale score 5 at the first pain assessment. In the experimental group (n = 19), each patient was assessed by the DOLOPLUS-2 scale at 2PM and 9PM each day for 5 days. If a patient's total score was 5, analgesics were prescribed and the patient was re-assessed approximately 3 hours later. In the control group (n = 20), data were collected from medical records over a 1-year period, and we matched the characteristics of the control group to that of the experimental group. We also reviewed nursing records to determine the number of times analgesics had been administered over the 5 days after the nurses had first recorded that the patient had experienced pain. ResultsAmong the 19 patients in the experimental group, 15 received pain medication because of a total pain score 5. Before treatment, their mean DOLOPLUS-2 scale score was 7.5 3.2, and their score significantly decreased to 2.9 +/- 2.1 (P < 0.001) after treatment. The experimental group also received significantly more treatments with analgesic medication than the control group ((2) = 16.033, P < 0.001, phi = 0.641). ConclusionThis study's findings suggested that the Japanese DOLOPLUS-2 scale could adequately identify pain in elderly individuals with moderate-to-severe dementia.
引用
收藏
页码:315 / 322
页数:8
相关论文
共 50 条
  • [41] Pain in older persons with severe dementia. Psychometric properties of the Mobilization-Observation-Behaviour-Intensity-Dementia (MOBID-2) Pain Scale in a clinical setting
    Husebo, Bettina S.
    Strand, Liv I.
    Moe-Nilssen, Rolf
    Husebo, Stein B.
    Ljunggren, Anne E.
    SCANDINAVIAN JOURNAL OF CARING SCIENCES, 2010, 24 (02) : 380 - 391
  • [42] Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain
    Hale, Martin E.
    Laudadio, Charles
    Yang, Ronghua
    Narayana, Arvind
    Malamut, Richard
    JOURNAL OF PAIN RESEARCH, 2015, 8 : 623 - 636
  • [43] Analgesic Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-Severe Pain After Open Abdominal Hysterectomy: A Phase 2 Randomized Clinical Trial
    Rechberger, Tomasz
    Mack, Randall J.
    McCallum, Stewart W.
    Du, Wei
    Freyer, Alex
    ANESTHESIA AND ANALGESIA, 2019, 128 (06) : 1309 - 1318
  • [44] Safety of Injectable HPβCD-Diclofenac in Older Patients with Acute Moderate-to-Severe Postoperative Pain: A Pooled Analysis of Three Phase III Trials
    Chelly, Jacques E.
    Lacouture, Peter G.
    Reyes, Christian Russel D.
    DRUGS & AGING, 2018, 35 (03) : 249 - 259
  • [45] Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain
    Imanaka, Keiichiro
    Tominaga, Yushin
    Etropolski, Mila
    Van Hove, Ilse
    Ohsaka, Masaki
    Wanibe, Mikio
    Hirose, Keiichiro
    Matsumura, Taka
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (10) : 1399 - 1409
  • [46] Safety of Co-Crystal of Tramadol-Celecoxib (CTC) in Patients with Acute Moderate-to-Severe Pain: Pooled Analysis of Three Phase 3 Randomized Trials
    Viscusi, Eugene R.
    Langford, Richard
    Morte, Adelaida
    Vaque, Anna
    Cebrecos, Jesus
    Sust, Mariano
    Gimenez-Arnau, Jose Maria
    de Leon-Casasola, Oscar
    PAIN AND THERAPY, 2024, 13 (06) : 1617 - 1631
  • [47] A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis
    Roberto, A.
    Greco, M. T.
    Legramandi, L.
    Galli, F.
    Galli, M.
    Corli, O.
    JOURNAL OF PAIN RESEARCH, 2017, 10 : 2123 - 2133
  • [48] Assessment of long-term safety and efficacy of Dupilumab therapy in patients with moderate-to-severe atopic dermatitis in the UAE: A real-life observational study
    Abdulwahhab, Waqas S.
    Zainalabdin, Sham
    Al-Areqi, Noor
    Amrane, Imene
    Alhashmi, Ahmed
    Aburuz, Omar
    Akour, Amal
    Beiram, Rami
    Aburuz, Salahdein
    PHARMACY PRACTICE-GRANADA, 2024, 22 (02):
  • [49] Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
    Mtibaa, Mondher
    Gupta, Subhajit
    Muthukumar, Madhusubramanian
    Marvel, Jessica
    Kaur, Harneet
    Ishikawa, Ryotaro
    Olivenstein, Ron
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 957 - 967
  • [50] Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study
    Pinter, Andreas
    Soliman, Ahmed M.
    Pivneva, Irina
    Ghanbariamin, Roksana
    Yang, Min
    Truong, Bang
    Puig, Luis
    Lebwohl, Mark
    DERMATOLOGY AND THERAPY, 2024, 14 (05) : 1259 - 1271